|Day Low/High||165.29 / 166.91|
|52 Wk Low/High||109.16 / 165.16|
The GOP is scrambling for votes on Obamacare Repeal.
"I had nothing to offer anybody except my own confusion." -- Jack Kerouac So, color me confused. But I will persevere and write "Takeaways!" While a lot didn't make sense, I suspect many traders/investors were caught "offsides." Peter Boockvar do...
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
There are nearly too many surging sectors to count.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
It's better to be early than wrong. Though being wrong isn't so awful.
Icahn may have a tough time finding interest in this behemoth.
Every single market indicator I look at is overbought. But it's likely that shorts and underperformers are buoying stocks. Some are at the most overbought in decades. The bond market is clearly not as sanguine on economic growth/corporate profi...
Integra hopes this deal will grow its revenue to $2 billion sooner than expected.
Amazon, J&J, IBM and others don't deserve this treatment.
They have become a referendum on Trump's plans for lower corporate taxes.
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.
Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.
Half the Dow components have reported and it's their impressive results that are driving indices up.
Jim Cramer says the Dow hitting 20,000 is different from previous big runs because the milestone comes during earnings season and allows traders to reevaluate.
The Dow Jones Industrial Average sports double-digit gains for the first time in three weeks, moving it closer to 20,000.